Emergence, Development, and Future of Cardio-Oncology in China

Ying Liu1, Yan-Li Zhang1, Ji-Wei Liu2, Feng-Qi Fang3, Jian-Ming Li3, Yun-Long Xia1
1Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
3Cardiovascular Division, University of Minnesota, Minneapolis, MN 55417, USA

As the development of early detection and therapies advances in cancer patients, mortality rates attributed to cancer have declined. In the United States, there are approximately 15.5 million cancer survivors, and the number will grow to more than 20 million by 2026 (http://www.cancer.org/cancer/news/news/report-number-of-cancer-survivors-continues-to-grow). Unfortunately, the improved survival in cancer patients from cancer therapy is achieved at the expense of treatment-induced adverse effects with CVD being one of the most frequent side effects [Supplementary Table 1].11 This may result from the direct cardiotoxicity of anticancer treatment or from the accelerated preexisting CVD or cardiovascular risk factors. CVD is now the second leading cause of long-term morbidity and mortality among cancer survivors,12-7

The presence of CVD may limit the treatment options for cancer. Here we share a case: A 60-year-old male patient with a 30-year history of smoking was diagnosed with non-ST-segment elevation myocardial infarction four years ago. Coronary angiography (CAG) showed 50% stenosis of the mid-left anterior descending (LAD) artery and 75% stenosis of the distal diagonal branch without percutaneous intervention. One year ago, he was diagnosed with squamous cell carcinoma of the left lung (cT2N0MX) and treated with afatinib. Due to the tumor progression, he underwent chemotherapy of gemcitabine and cisplatin in place of afatinib. On the 7th day of the second chemotherapy cycle, the patient presented with sudden and persistent chest pain with subsequent electrocardiogram demonstrating ST-segment elevation myocardial infarction. CAG confirmed the occlusion in the proximal LAD for which percutaneous coronary intervention treatment was provided. Gemcitabine was discontinued in the subsequent chemotherapy for the considering that the acute myocardial infarction may induced by gemcitabine. Such a case is one of the many that we have encountered where cancer was complicated by cardiovascular disease (CVD). Cardiovascular toxicity induced by cancer treatment is a common and pressing issue for cardiologists and oncologists.

To sustain survival improvement achieved using modern cancer therapies, the importance of CVD in cancer patients has been increasing recognized, leading to the emergence and development of the cross-disciplinary field of cardio-oncology. In 2000, the first onco-cardiology unit was established at the University of Texas MD Anderson Cancer Center, and in 2009, International Cardio-Oncology Society was established by the European Institute of Oncology.8 The International Conference on Cancer and the Heart has been held in Texas every 2 years since 2010. Along with many publications from clinical and pathological observations or clinical trials, cardio-oncology specialists all over the world have been concentrating on their efforts in investigating epidemiologic burden, biomarkers and imaging for CVD prediction, and risk stratification and the effects of cardio-protective strategies. Just during 2016, four practice guidelines or consensus was published on the evaluation, prevention, and management of CVD in cancer survivors. These have set the foundation for this new discipline.1,9-11 Recently, an opinion paper on cardiovascular toxicity related to anticancer treatment from the working group on cardio-oncology of the Korean Society of Echocardiography provided more information.12

As reported by the National Cancer Center of China, the incidence and mortality of cancer have increased...
In addition, treating CVDs and interventional therapies such as the use of antiplatelet drugs produces a hypercoagulable state, it also predisposes cancer patients with preexisting CAD. While cancer by targeted drug therapy and traditional chemotherapy can be precipitated acute myocardial infarction can be mitigated by prophylactic use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or beta blockers could prevent anthracycline/trastuzumab-induced cardiotoxicity in adult cancer populations. The above-mentioned ESC Position Paper provides screening and evaluation guidelines from Europe for Chinese cancer patients. In 2013, the Chinese Society of Clinical Oncology and the Chinese Medical Association published guidelines on the prevention and treatment of anthracycline-related cardiotoxicity and published updated version in 2017. In early 2016, a panel of 17 experts including cardiologists, oncologists, hematologists, cardiac imaging specialists, and basic research scientists initiated the China cardio-oncology network. The first workshop was held on June 5, 2016, in Dalian, China. Experts discussed the most appropriate approach to launch cardio-oncology in China. A second workshop swiftly followed on August 12, 2016, in Beijing, the group confirmed the concept and scope of the cardio-oncology program in China, which includes treatment-associated CVD in cancer patients, comorbidity of CVD and cancer, shared risk factors in cancer, and CVD and cardiac tumors.

Cardiovascular toxicity from chemotherapy, radiation therapy, targeted drug therapy, and surgery-related adverse effects all contribute to the cardiovascular events in cancer patients. Age, preexisting CVD risk factors (smoking, obesity, sedentary habit, family history of premature CVD, etc.), specific chemotherapy agents and dosage, radiotherapy area, and dosage are common risk factors closely related to cardiovascular toxicity. According to the 2016 European Society of Cardiology (ESC) Position Paper on cancer treatments and cardiovascular toxicity, cardiovascular complications are classified into nine main categories: myocardial dysfunction and heart failure, coronary artery disease (CAD), valvular disease, arrhythmias, especially those induced by QT-prolonging drugs, arterial hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension, and pericardial complications. An increasing body of evidence suggests that targeting modifiable risk factors, early prevention, and treatment can mitigate the degree of cardiotoxicity and early detection is increasingly important. For example, prophylactic use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or beta blockers could prevent anthracycline/trastuzumab-induced cardiotoxicity in adult cancer populations. The above-mentioned ESC Position Paper guideline provides screening and evaluation recommendations or suggestions for every category.

As illustrated in the case mentioned in the beginning of this article, acute myocardial infarction can be precipitated by targeted drug therapy and traditional chemotherapy in cancer patients with preexisting CAD. While cancer produces a hypercoagulable state, it also predisposes patients to bleeding, which limits options for medical and interventional therapies such as the use of antiplatelet drugs and anticoagulants. Similarly, when a thromboembolic event or atrial fibrillation occurs in cancer patients, it is difficult to balance the bleeding risk and provide the more appropriate anticoagulation strategies. Although the current guidelines offer some general recommendations, clinical trials are urgently needed, especially on the suitability of these practice guidelines from Europe for Chinese cancer patients.

In recent years, as aging population becomes an increasing trend in China, a number of common risk factors presented in cancer and CVD patients, including obesity, diet, smoking, diabetes mellitus, and hyperlipidemia, become more prevalent. As an example, there is convincing evidence supporting the correlation between obesity and esophageal adenocarcinoma, pancreatic, liver, colorectal, postmenopausal breast, endometrial, and kidney cancer. Epidemiological data suggest that up to 20% of malignancies could be related to weight gain and obesity. As a report by the American Diabetes Association in 2010, there is convincing evidence associating colorectal, breast, endometrial, liver, pancreatic, and bladder cancers with diabetes mellitus. In addition, treating CVDs and CVD-related risk factors may affect the risk and prognosis of cancer. For example, ACEI showed an association with breast cancer recurrence; aspirin reduced the risk of colorectal cancer by 24%, prediagnostic statin use reduces the risk of lethal prostate cancer; and statin use either before or after diagnosis of cancer was associated with improved cancer specific as well as overall survival. The overlap of risk factors in CVD and cancer suggests that the two seemingly different diseases might share some common biological molecular mechanisms such as inflammation, oxidative stress, and reactive oxygen species. Controlling CVD risk factors can help reduce the risk of cancer. Further understanding of the delicate interaction between CVD and cancer may lead to better prevention, earlier detection, and safer treatment strategies.

Cardiac tumors can be divided into primary and secondary cardiac tumors. A 20-year experience with review of 12,485 consecutive autopsies showed that their incidences are 0.056% and 1.23%, respectively. For secondary cardiac tumors, the common primary sources are carcinoma of the lung, breast, pancreatic, esophageal, liver, gastric and lymphoma, and leukemia. Seventy-five percent of patients with cardiac tumors are benign. Primary malignant cardiac tumors represented by sarcomas and non-Hodgkin lymphomas are rare and associated with a grave prognosis. Lestuzzi et al. stressed the importance of the multidisciplinary approach and involvement of cardio-oncologists in making the diagnostic and treatment decisions. The prognosis may be improved by a careful planning of surgery and through the use of multimodality treatment including chemotherapy and radiation therapy. A strict follow-up protocol must be planned even following complete cure.

After the workshops, the expert panel published a proposal to call attention to the cardio-oncology and strengthened...
physicians’ education through national medical meetings and online promotion and established international exchanges and cooperation. The first cardio-oncology clinic in China was established in the First Affiliated Hospital of Dalian Medical University in August 22, 2016, and a preliminary cardio-oncology consultation program was performed simultaneously [Figure 1]. Some cancer centers also set up cardiology department to provide CVD care for cancer patients after the cardio-oncology workshops.

The First China Cardio-Oncology Conference entitled “Prevention, Early Intervention, Multidisciplinary Collaboration” was successfully held in Dalian on November 18–19, 2016. Meeting topics included the current status and future directions of cardio-oncology, overview of anticancer therapies and associated cardiotoxicity, establishment of cardio-oncology units in domestic hospitals, echocardiographic evaluation, cardiac tumors, basic research, and case presentations. It attracted over 300 attendees from around the country, indicating the increased clinician awareness on the educational initiatives and the importance of this new discipline. Subsequently, numerous cardio-oncology forums were set up in academic conferences on cardiovascular and oncology for communication and education.

In addition, it is encouraging that the research work on cardio-oncology in China has achieved progression both in basic and clinical research. For example, further understanding on the relationship between end-stage carcinoma and acquired long QT syndrome might provide a new predictor of risk of all-cause mortality for cancer patients,[29] and we speculate that correction of the related risk factors will improve the prognosis of cancer patients. Animal experiments have explored potential specific protection measure against doxorubicin-induced Systematic medical history and physical examination

Figure 1: The cardio-oncology consultation program for cancer patients of the First Affiliated Hospital of Dalian Medical University. ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor antagonist; BNP: Brain natriuretic peptide; CAD: Coronary artery disease; CVD: Cardiovascular disease; cTnI: Cardiac troponin I; ECG: Electrocardiogram; HF: Heart failure; HTN: Hypertension; LVEF: Left ventricular ejection fraction.
The booming development of cardio-oncology in China has beyond our expectation. Although the cardio-oncology is rapidly growing in China, there are few Chinese cardio-oncologists because of the complexity of cancer and anticancer therapy and insufficient communication between cardiology and oncology before the recognition of cardio-oncology as an established and recognized specialty. A cardio-oncologist should be a health-care provider who is focused on the prevention, early detection, and management and treatment of cardiac injury that may stem from cancer or cancer therapies. To develop the discipline, we need to first establish a training system based on the experience from Europe and America. The training curriculum should be targeted to cardiologists and focused on cancer and anticancer treatments as well as the associated cardiotoxicity. It is important to increase our collective understanding and ability to modify the interactions between cancer and cardiovascular health.

The main focus of cardio-oncology is to improve the prognosis of cancer patients. The cardio-oncology specialty is at its infant stage in China. Currently, the lack of evidence to guide clinical decision-making and recommendations suitable for Chinese patients in cardio-oncology is a major challenge for health-care professionals. Several studies suggest that early detection of cardiovascular toxicity is possible through risk stratification before initiation of cancer therapy and periodic evaluation with physical examinations, echocardiography, magnetic resonance imaging, multigated acquisition scan, electrocardiogram, and biomarkers. ACEI/ARB and beta-blockers can reduce cancer therapy-related cardiac dysfunction and reduce mortality. The Society for Cardiovascular Angiography and Interventions recommends prechemotherapy cardioprotection. For patients with established CAD and without contraindications, adding or continuing ACEI and beta-blockers (preferably carvedilol or nebivolol) may provide additional cardioprotection. Based on the current experience, multicenter and multidiscipline association is optimal to create the clinical database and implement large prospective studies to develop the standard programs for CVD screening, prevention, treatment, and management.

The mechanisms of cancer and anticancer treatment-related cardiovascular toxicity are not very well studied. Basic, translational, and clinical research is needed to explore the molecular pathways of the CV toxicity from cancer therapies and to improve the effective interventions.

In summary, cardio-oncology is a new cross-discipline specialty with a focus on the cardiovascular health of cancer patients and cancer survivors. With the increasing recognition and the support of numerous cardiologists, oncologists, hematologists, cardiac imaging specialists, and basic research scientists, cardio-oncology has been steadily gaining attention in China. In addition to establishing multidiscipline training programs for cardiologists specializing in cardio-oncology, clinical and basic medical research will be urgently needed to provide clinical data and evidence-based approach in cardiovascular care unique to Chinese patients with cancer.

Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggianno R, Galdersi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-801. doi: 10.1093/eurheartj/ehw211.
2. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One 2010;5:e9584. doi: 10.1371/journal. pone.0009584.
3. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA, et al. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584-98. doi: 10.1093/jnci/djq366.
4. Bodai BI, Tuso P. Breast cancer survivorship: A comprehensive review of long-term medical issues and lifestyle recommendations. Perm J 2015;19:48-79. doi: 10.7812/TPP/14-241.
5. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41. doi: 10.3322/caac.21149.
6. Curigliano G, Cardinale D, Dent S, Criscitiello A, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016;66:309-25. doi: 10.3322/caac.21341.
7. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9. doi: 10.1001/jama.294.10.1255.
8. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 2010;53:88-93. doi: 10.1016/j.pcad.2010.06.002.
9. Armenian SH, Lachettt C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 2017;13:270-5. doi: 10.1200/JOP.2016.018770.
10. Virani SA, Dent S, Breiden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society Guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 2016;32:831-41. doi: 10.1016/j.cjca.2016.02.078.
11. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad latino americana de cardiologia
intervencionista). Catheter Cardiovasc Interv 2016;87:E202-23. doi: 10.1002/ccd.26379.

12. Kim H, Chung WB, Cho KI, Kim BJ, Seo JS, Park SM, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: An opinion paper from the working group on cardio-oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound 2018;26:1-25. doi: 10.4250/jcu.2018.26.1.1.

13. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. doi: 10.3322/caac.21338.

14. Garner M, Routledge T, King JE, Pilling JE, Veres L, Harrison-Phipps K, et al. New-onset atrial fibrillation after anatomic lung resection: Predictive factors, treatment and follow-up in a UK thoracic centre. Interact Cardiovasc Thorac Surg 2017;24:260-4. doi: 10.1093/icvts/ivw348.

15. Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: Analysis of the society of thoracic surgeons general thoracic surgery database. Ann Thorac Surg 2010;90:368-74. doi: 10.1016/j.athoracsur.2010.03.100.

16. Imperatori A, Mariscalco G, Riganti G, Rotolo N, Conti V, Dominioni L, et al. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiovasc Surg 2012;7:74. doi: 10.1186/1749-8090-7-4.

17. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Carril TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and Carvedilol in patients submitted to intensive ChemOTherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol 2013;61:2355-62. doi: 10.1016/j.jacc.2013.02.072.

18. Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: Implications for preventive health and clinical care in oncology patients. Can J Cardiol 2016;32:909-7. doi: 10.1016/j.cjca.2016.04.008.

19. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133:1104-14. doi: 10.1161/CIRCULATIONAHA.115.020406.

20. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-65. doi: 10.1634/theoncologist.2009-0285.

21. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-85. doi: 10.2337/dc10-0666.

22. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res Treat 2011;129:549-56. doi: 10.1007/s10549-011-1505-3.

23. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50. doi: 10.1016/S0140-6736(10)61543-7.

24. Mucci LA, Stampfer MJ. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol 2014;32:1-2. doi: 10.1200/JCO.2013.53.2770.

25. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J, et al. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat Rev 2015;41:554-67. doi: 10.1016/j.ctrv.2015.04.005.

26. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993;117:1027-31.

27. Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Cardiac tumors – Diagnosis and surgical treatment. Dtsch Arztebl Int 2014;111:205-11. doi: 10.3238/arztebl.2014.0205.

28. Lestuzzi C, De Paoli A, Baresic T, Miolo G, Buonadonna A. Malignant cardiac tumors: Diagnosis and treatment. Future Cardiol 2015;11:485-500. doi: 10.2217/fca.15.10.

29. Yu H, Zhang L, Liu J, Liu Y, Kowey PR, Zhang Y, et al. Acquired long QT syndrome in hospitalized patients. Heart Rhythm 2017;14:974-8. doi: 10.1016/j.hrthm.2017.03.014.

30. Wang L, Zhang TP, Zhang Y, Bi HL, Guan XM, Wang HX, et al. Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein. Sci Rep 2016;6:28399. doi: 10.1038/ srep28399.

31. Lenihan DI, Hartlage G, DeCarla J, Blaes A, Finet JE, Lyon AR, et al. Cardio-oncology training: A Proposal from the International Cardi Oncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary specialty. J Card Fail 2016;22:465-71. doi: 10.1016/j.cardfail.2016.03.012.

32. Gillebert TC, Brooks N, Fontes-Carvalho R, Fras Z, Gueret P, Lopez-Sendon J, et al. ESC core curriculum for the general cardiologist (2013). Eur Heart J 2013;34:2381-411. doi: 10.1093/ eurheartj/eh3234.
**Supplementary Table 1: Incidence of common cardiovascular side effects associated with chemotherapy drugs**

| Chemotherapy agents       | Left ventricular dysfunction (%) | Myocardial ischemia (%) | Hypertension (%) | Increase in QTc > 60 ms (%) |
|---------------------------|----------------------------------|-------------------------|------------------|-----------------------------|
| **Anthracyclines**        |                                  |                         |                  |                             |
| Doxorubicin (Adriamycin)  |                                  | NA                      | NA               | 11–14                       |
| 400 mg/m²                 |                                  | 3–5                     | NA               |                             |
| 550 mg/m²                 |                                  | 7–25                    | NA               |                             |
| 700 mg/m²                 |                                  | 18–48                   | NA               |                             |
| Idarubicin (>90 mg/m²)    | 5–18                             | NA                      | NA               | NA                          |
| Epirubicin (>900 mg/m²)   | 0.9–11.4                         | NA                      | NA               | NA                          |
| Mitoxantrone (>120 mg/m²) | 2.6                              | NA                      | NA               | NA                          |
| **Alkylating agents**     |                                  |                         |                  |                             |
| Cyclophosphamide          | 7–28                             | NA                      | NA               | NA                          |
| Cisplatin                 | NA                               | 0.2–12                  | NA               | NA                          |
| **Antimetabolites**       |                                  |                         |                  |                             |
| Clofarabine               | 27                               | NA                      | NA               | NA                          |
| **Antimicrotubule agents**|                                  |                         |                  |                             |
| Paclitaxel                | <1                               | 0.2–4                   | NA               | NA                          |
| **Monoclonal antibodies** |                                  |                         |                  |                             |
| Trastuzumab               | 1.7–20.1                         | NA                      | NA               | NA                          |
| Bevacizumab               | 1.6–4                            | 1–6                     | 23.6             | NA                          |
| **Small molecule tyrosine kinase inhibitors** | | | | |
| Axitinib                  | NA                               | NA                      | 40.1             | NA                          |
| Sunitinib                 | 2.7–19                           | 1–13                    | 21.6             |                             |
| Vandetanib                | NA                               | NA                      | 24.2             | 12–15                       |
| Pazopanib                 | 7–11                             | 2–10                    | NA               | NA                          |
| Sorafenib                 | 4–8                              | 1–2                     | 15.3             | NA                          |
| **Others**                |                                  |                         |                  |                             |
| Arsenic trioxide          | NA                               | NA                      | NA               | 35                          |

NA: Not available.